Cagrilintide
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. Its native half-life is measured in minutes. Cagrilintide extends that conversation to approximately seven days through fatty-acid acylation – a C20 diacid chain attached via a hydrophilic linker that promotes albumin binding and slows renal clearance. The result is a molecule that sustains amylinergic signalling across the full interval between weekly injections, allowing the brain’s satiety architecture to receive a continuous, physiologically coherent signal rather than a transient postprandial pulse.
Calcitonin receptor activation in the area postrema and nucleus tractus solitarius inhibits gastric emptying and engages hindbrain satiety circuits. This is the primary anorectic mechanism of amylin agonism.
CALCR association with RAMP1 and RAMP3 generates the AMY1 and AMY3 receptor subtypes, extending signaling to hypothalamic arcuate and paraventricular populations. Both heterodimers are engaged at therapeutic doses of cagrilintide.
Amylinergic signaling attenuates postprandial glucagon secretion, reducing hepatic glucose output and blunting glycemic excursions. This effect operates independently of GLP-1 tone.
C20 diacid acylation promotes albumin binding and slows renal clearance, extending the native half-life from minutes to approximately seven days. This pharmacokinetic profile is what enables once-weekly co-administration with semaglutide.
What we observe
Seen with Cagrilintide: less eating, more loss
The outcomes below reflect patterns reported in controlled clinical investigations of cagrilintide, both as monotherapy and in combination with semaglutide. They describe what investigators observed across study populations. They do not constitute predictions for any individual. Aeterna does not prescribe, dispense, or sell.
01
Sustained body-weight reduction
02
Appetite and meal-size reduction
03
Postprandial glycaemic attenuation
04
Additive weight loss in combination with semaglutide
05
Favourable cardiovascular risk marker profile
06
Tolerability profile consistent with amylin class
Evidence
Study results so far
Three studies anchor the current evidence base for cagrilintide in humans. Each is cited with its primary finding and a representative statistic. The field is moving; these entries reflect literature available through early 2025. Readers are encouraged to consult primary sources directly.
Cagrilintide dose-escalation in adults with overweight or obesity: a randomised, double-blind, placebo-controlled, Phase II trial
Participants (n=706) were randomised to five dose levels of cagrilintide (0.3–4.5 mg weekly) or placebo over 26 weeks. Body weight decreased in a dose-dependent manner across all active arms. The 4.5 mg cohort achieved a mean reduction of 10.8% from baseline. Nausea was the most common adverse event, predominantly mild-to-moderate and transient. No clinically significant hypoglycaemia was observed.
Complementary mechanisms of cagrilintide and semaglutide in combination: receptor pharmacology and early clinical observations from the REDEFINE programme
A mechanistic review and Phase II combination substudy (n=96) demonstrated that co-administration of cagrilintide and semaglutide produced additive reductions in caloric intake and body weight relative to either monotherapy. Receptor binding studies confirmed non-overlapping target engagement – CALCR/RAMP versus GLP-1R – supporting the pharmacological rationale for combination. Tolerability was manageable with a structured escalation protocol.
CagriSema versus semaglutide 2.4 mg for weight management in adults with obesity: results from REDEFINE 1
The REDEFINE 1 trial (n=3417) compared the fixed-ratio combination of cagrilintide 2.4 mg and semaglutide 2.4 mg (CagriSema) against semaglutide 2.4 mg monotherapy and placebo over 68 weeks. CagriSema produced a mean weight reduction of 22.7% from baseline, compared with 16.1% for semaglutide alone. The combination met its primary endpoint. Gastrointestinal adverse events were the most common reason for discontinuation in both active arms.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: store frozen at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.
- Reconstituted solution: stable for up to 28 days at 2–8 °C when prepared with bacteriostatic water.
- Do not use if solution appears cloudy, discoloured, or contains visible particulate matter.
- Allow vial to reach room temperature for 10–15 minutes before reconstitution to reduce foaming.
Side effects
What members describe
- Nausea - most common; typically dose-dependent and attenuates after 2–4 weeks at each dose level.
- Vomiting - less frequent than nausea; most often associated with rapid escalation or concurrent high-fat meals.
- Decreased appetite - an expected pharmacodynamic effect; monitor for excessive caloric restriction.
- Injection-site reactions - mild erythema or induration; rotate injection sites systematically.
- Fatigue - reported in a minority of participants during early escalation; generally transient.
Contradictions
Reasons to abstain
- Personal or family history of medullary thyroid carcinoma - calcitonin receptor agonism warrants caution pending further long-term data.
- Multiple endocrine neoplasia syndrome type 2 (MEN2) - contraindicated by class mechanism.
- Pregnancy or planned pregnancy - no adequate human safety data; use is not supported.
- Severe gastroparesis or clinically significant gastric motility disorder - gastric-emptying delay may be exacerbated.
- Hypersensitivity to amylin analogues or any excipient in the formulation.
Synergies
Best combos for Cagrilintide
Cagrilintide’s receptor specificity – CALCR/RAMP rather than GLP-1R – makes it a mechanistically coherent partner for agents operating through distinct pathways. The combinations below reflect pharmacological logic observed in the clinical literature. They are presented as educational context, not as protocols. Aeterna does not prescribe, dispense, or sell.
FAQ
Your questions, patiently answered
Pramlintide is a short-acting amylin analogue administered three times daily with meals, reflecting the native postprandial secretion pattern of amylin. Cagrilintide achieves the same receptor engagement – CALCR/RAMP – but through fatty-acid acylation that extends its half-life to approximately seven days, enabling once-weekly subcutaneous dosing. The pharmacological target is identical; the pharmacokinetic architecture is fundamentally different.
No. Cagrilintide does not bind the GLP-1 receptor. It is a selective agonist at calcitonin receptor and amylin receptor subtypes (AMY1, AMY3). Its weight-loss mechanism is distinct from semaglutide or liraglutide, which is precisely why the combination with GLP-1 receptor agonists produces additive rather than merely redundant effects.
The acylation strategy – attaching a C20 fatty diacid chain via a hydrophilic linker – promotes reversible binding to circulating albumin. This dramatically slows renal filtration and proteolytic degradation, extending the effective half-life from minutes (native amylin) to approximately seven days. The same engineering principle underlies semaglutide’s extended half-life, though the linker chemistry differs.
In isolation, cagrilintide does not appear to cause clinically significant hypoglycaemia. Its glucagon-suppressive effect is glucose-dependent – active postprandially, attenuated during fasting – which preserves the counter-regulatory response. When combined with insulin or sulphonylureas, the risk profile warrants closer monitoring, as with any agent that reduces postprandial glucose.
As of the time of this monograph, cagrilintide is investigational. It has not received approval from the FDA, EMA, or equivalent regulatory bodies as a standalone agent. The fixed-ratio combination with semaglutide (CagriSema) is under regulatory review following Phase III REDEFINE programme results. Regulatory status evolves; readers should consult current agency databases.
The prevailing hypothesis is that amylinergic and GLP-1 satiety circuits are anatomically and functionally distinct – the former centred on brainstem area postrema and NTS, the latter more broadly distributed including vagal afferents and hypothalamic nuclei. Engaging both simultaneously may approach a more complete satiety signal than either pathway alone can produce. This remains a working hypothesis; the neuroscience of appetite is not fully mapped.
In the same family
Further reading in the curriculum - adjacent compounds worth understanding.
Sourcing · Independently verified
When you're ready, source thoughtfully.